Regulation & law · 18/12/2015Updated: 10/17/2026 · 1 min read
National Cancer Institute to Grant Exclusive Patent License to Heliome Biotech for Farnesoid X Receptor Inhibitor
The National Cancer Institute is considering granting an exclusive patent license to Heliome Biotech, Inc. to develop a small molecule farnesoid X receptor inhibitor, as outlined in U.S. patents and patent applications.